New prevention study now open for enrollment – Help us find out if a low dose immunotherapy can STOP-T1D
TrialNet researchers are testing low-dose anti-thymocyte globulin (ATG), an immunotherapy, to find out if it can delay or prevent type 1 diabetes (T1D) in people at high risk of clinical diagnosis (Stage 3) within two years.
Diabetes camps provide summer fun and independence
DECA Executive Director Terry Ackley, and his wife, Carol, volunteered at Camp Seale Harris for several years before he was hired as the Camp’s executive director in 1995. He served in that role until joining DECA in 2012. Pictured here: Terry and Carol (right) with daughter, Emily (left), son-in-law, Patrick, and granddaughter, Vivienne.
Study findings shed new light on abatacept’s impact on type 1 diabetes progression, suggest direction for additional research
Findings from the TrialNet Abatacept Prevention Study, published online in Diabetes Care, provide important new information about how abatacept impacts type 1 diabetes (T1D) progression and suggest direction for additional research.